News | Artificial Intelligence | November 24, 2020

FDA Clears First AI-Powered Algorithm Suite for Personal ECG Monitoring

AliveCor introduces new generation of of interpretive ECG algorithms

The U.S. Food and Drug Administration (FDA) has cleared AliveCor's Kardia AI V2 next generation of interpretive artificial intelligence (AI)-based personal electrocardiogram (ECG) algorithms.

The U.S. Food and Drug Administration (FDA) has cleared AliveCor's Kardia AI V2 next generation of interpretive artificial intelligence (AI)-based personal electrocardiogram (ECG) algorithms.

November 24, 2020 — The U.S. Food and Drug Administration (FDA) has cleared AliveCor's next generation of interpretive artificial intelligence (AI)-based personal electrocardiogram (ECG) algorithms.

"Kardia AI V2 is the most sophisticated AI ever brought to personal ECG," said AliveCor CEO Priya Abani. "This suite of algorithms and visualizations will provide the platform for delivery of new consumer and professional service offerings beyond AFib, by allowing a much wider range of cardiac conditions to be determined on a personal ECG device."

AliveCor's KardiaMobile and KardiaMobile 6L devices, along with the Kardia app, allow users to take a 30-second ECG and receive instant determinations of multiple cardiac conditions. This new FDA 510(K) clearance provides detail and fidelity unlike any previously seen in personal ECG devices including:
   • A "Sinus Rhythm with Premature Ventricular Contractions (PVCs)" determination if two or more ventricular ectopic beats are detected. PVCs are a common occurrence where extra heartbeats originate in the bottom chamber of the heart and occur sooner than the next expected regular heartbeat. After the PVC beat, a pause usually occurs, which causes the next normal heartbeat to be more forceful. When one feels the heart "skip a beat," it is this more forceful beat that is felt.
   • A "Sinus Rhythm with Supraventricular Ectopy (SVE)" determination if narrow-complex ectopy, such as premature atrial contractions (PACs), are detected. PACs are similar to PVCs, but these beats originate in the top chamber of the heart, however not in the heart's natural pacemaker, the Sinus Node.
    • A "Sinus Rhythm with Wide QRS," determination for QRS intervals of 120ms or longer.  Wide QRS indicates that the activation of the bottom chamber of the heart is taking longer than expected. This could indicate a bundle branch block in which there is a delay in the passage of heart's electrical signals along the bottom of the heart.
   • A reduced number of "Unclassified" readings, thereby giving users more reliable insight into their heart rhythms.
   • Improved sensitivity and specificity on the company's "Normal" and "Atrial Fibrillation" algorithms, giving users fewer false positives, fewer false negatives, and even greater confidence in Kardia determinations.
   • New visualizations, including average beat, PVC identification, and a tachogram.

AliveCor expects this new suite of advanced determinations will augment telehealth services and provide the technology foundation for a new range of professional and consumer services including the launch of:
   • Advanced ECG determination services within KardiaCare, the company's remote heart care service for consumers.
   • The Kardia Heart Health Report (HHR), a cardiologist-backed patient heart risk assessment report.
   • A professional ambulatory monitoring service, using the AliveCor six-lead ECG device at home, bringing greater comfort and convenience over legacy technologies.
   • Chronic heart disease management, which combines human-backed and digital care plans to manage the heart health of high-risk employee populations.

This new FDA clearance positions AliveCor to deliver AI-based remote cardiological services for the vast majority of cases when cardiac patients are not in front of their doctor. AliveCor's goal is to help cardiologists efficiently provide the best possible 24/7 service to their patients.

Today, KardiaMobile and KardiaMobile 6L are the most clinically validated personal ECG devices in the world, and provide instant detection of Normal Sinus Rhythm, Atrial Fibrillation, Bradycardia, and Tachycardia. The new determinations and services will be available in 2021.

For more information: alivecor.com

 

Related Artificial intelligence Application in Echo and Cardiology:

New Cardiac Diagnostic Tool Helps Automate Point-of-Care Ultrasound Screening

JAMA Cardiology Article Shows Effectiveness of AI-Guided Ultrasound Software 

Mayo Clinic Uses Artificial Intelligence to Help Assess Cardiac Danger From COVID-19

Northwestern Medicine Introduces Artificial Intelligence to Improve Ultrasound Imaging

FDA Clears Ultromics Echocardiography AI for Automated Identification of Coronary Artery Disease

 

TomTec Releases New Echocardiography Technologies With AI and Auto Quantification

VIDEO: AI-Assisted Automatic Ejection Fraction for Point-of-Care Ultrasound

New Cardiac Diagnostic Tool Helps Automate Point-of-Care Ultrasound Screening

FDA Clears Caption Health AI-assisted Point-of-care Ejection Fraction Evaluation

WEBINAR: Intelligently Efficient Adult Echo Structured Reporting

 

What is New in Cardiology? A Review of All Major Emerging Technologies for Heart Diseases

Expanded AI-based Echocardiography Analysis and Reporting Added to Konica Minolta Exa Cardio PACS 

More Than 50,000 Children Screened for Congenital Heart Defects Using AI-enabled Stethoscopes

Related Content

Cloud AI software-as-a-service (SaaS) can help streamline workflows and increase throughput, enabling echocardiographers to better measure global longitudinal strain (GLS) more routinely without impacting productivity. This is an example of the Ultromics EchoGo Core artificial intelligence algorithm with fully automates GLS.

Cloud artificial intelligence (AI) software-as-a-service (SaaS) can help streamline workflows and increase throughput, enabling echocardiographers to better measure global longitudinal strain (GLS) more routinely without impacting productivity. This is an example of the Ultromics EchoGo Core artificial intelligence algorithm, which fully automates GLS. Learn more at www.ultromics.com.

Feature | Artificial Intelligence | March 16, 2021
Heart failure (HF) is a prevalent ye
Ultromics will offer EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

News | Artificial Intelligence | January 06, 2021
January 6, 2021 — The U.S.
An example of a body composition analysis of an abdominal CT slice with the subcutaneous fat in green, skeletal muscle red and visceral fat in yellow. This was automatically identified and analyzed via a deep learning algorithm to assess the risk for heart attack and stroke in more than 12,000 patients. #RSNA2020 #RSNA20 #RSNA

An example of a body composition analysis of an abdominal CT slice with the subcutaneous fat in green, skeletal muscle red and visceral fat in yellow. This was automatically identified and analyzed via a deep learning algorithm to assess the risk for heart attack and stroke in more than 12,000 patients.

Feature | Artificial Intelligence | December 02, 2020
December 2, 2020 – Automated deep learning analysis of abdominal...
Dia's LVivo artificial intelligence software can help automate many features of echocardiograms to speed workflow and aid novice users. The software is now integrated into the Konica Minolta Exa PACS.

Dia's LVivo artificial intelligence software can help automate many features of echocardiograms to speed workflow and aid novice users. The software is now integrated into the Konica Minolta Exa PACS. 

News | Artificial Intelligence | November 12, 2020
November 12, 2020 – Konica Minolta Healthcare Americas Inc. and DiA Imaging Analysis Ltd.
The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

Feature | Artificial Intelligence | September 29, 2020 | Joe Fornadel, J.D., and Wes Moran, J.D.
The number of Federal Drug Administration (FDA)-approved AI-based algorithms is significant and has grown at a steady
Selfied might be used with AI to identify patients with heart disease. Getty Images

Getty Images

News | Artificial Intelligence | August 24, 2020
August 24, 2020 — Sending a photo selfie to the doctor could be a cheap and simple way of detecting heart disease usi
aption Health a leader in medical AI technology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated version of Caption Interpretation, which uses artificial intelligence (AI) to enable clinicians to obtain quick, easy and accurate measurements of cardiac ejection fraction (EF) at the point of care.

Caption Health a leader in medical AI technology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated version of Caption Interpretation, which uses artificial intelligence (AI) to enable clinicians to obtain quick, easy and accurate measurements of cardiac ejection fraction (EF) at the point of care.

News | Artificial Intelligence | August 19, 2020
August 19, 2020 — Caption Health a leader in medical AI technology, has received U.S.
In February 2020, the U.S. Food and Drug Administration (FDA) cleared artificial intelligence software to assist in the acquisition of cardiac ultrasound images. The Caption Guidance software from Caption Health is an accessory to compatible diagnostic ultrasound systems and uses artificial intelligence to help the user capture images of a patient’s heart that are of acceptable diagnostic quality. It is aimed at point of care ultrasound (POCUS) exams, where users may not be regular sonographers.

In February 2020, the U.S. Food and Drug Administration (FDA) cleared artificial intelligence software to assist in the acquisition of cardiac ultrasound images. The Caption Guidance software from Caption Health is an accessory to compatible diagnostic ultrasound systems and uses artificial intelligence to help the user capture images of a patient’s heart that are of acceptable diagnostic quality. It is aimed at point of care ultrasound (POCUS) exams, where users may not be regular sonographers.

Feature | Artificial Intelligence | August 18, 2020 | Dave Fornell, Editor
The No.